CN117838875B - 用于局部递送治疗剂的药物递送系统以及其用途 - Google Patents

用于局部递送治疗剂的药物递送系统以及其用途 Download PDF

Info

Publication number
CN117838875B
CN117838875B CN202311685488.1A CN202311685488A CN117838875B CN 117838875 B CN117838875 B CN 117838875B CN 202311685488 A CN202311685488 A CN 202311685488A CN 117838875 B CN117838875 B CN 117838875B
Authority
CN
China
Prior art keywords
methyl
amino
pyrrolo
cyanoacetyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202311685488.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN117838875A (zh
Inventor
张�浩
张纬江
冯立春
吴国龙
李大峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coval Biopharma (Shanghai) Co Ltd
Original Assignee
Coval Biopharma (Shanghai) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coval Biopharma (Shanghai) Co Ltd filed Critical Coval Biopharma (Shanghai) Co Ltd
Publication of CN117838875A publication Critical patent/CN117838875A/zh
Application granted granted Critical
Publication of CN117838875B publication Critical patent/CN117838875B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202311685488.1A 2020-07-15 2021-07-13 用于局部递送治疗剂的药物递送系统以及其用途 Active CN117838875B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102115 2020-07-15
CN2020102115 2020-07-15
CN202180049488.5A CN115867319B (zh) 2020-07-15 2021-07-13 用于局部递送治疗剂的药物递送系统以及其用途
PCT/CN2021/105899 WO2022012492A1 (en) 2020-07-15 2021-07-13 Drug delivery system for locally delivering therapeutic agents and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202180049488.5A Division CN115867319B (zh) 2020-07-15 2021-07-13 用于局部递送治疗剂的药物递送系统以及其用途

Publications (2)

Publication Number Publication Date
CN117838875A CN117838875A (zh) 2024-04-09
CN117838875B true CN117838875B (zh) 2025-01-24

Family

ID=79555042

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311685488.1A Active CN117838875B (zh) 2020-07-15 2021-07-13 用于局部递送治疗剂的药物递送系统以及其用途
CN202180049488.5A Active CN115867319B (zh) 2020-07-15 2021-07-13 用于局部递送治疗剂的药物递送系统以及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180049488.5A Active CN115867319B (zh) 2020-07-15 2021-07-13 用于局部递送治疗剂的药物递送系统以及其用途

Country Status (10)

Country Link
US (1) US20230256106A1 (cg-RX-API-DMAC7.html)
EP (1) EP4181963A4 (cg-RX-API-DMAC7.html)
JP (1) JP7870259B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230040957A (cg-RX-API-DMAC7.html)
CN (2) CN117838875B (cg-RX-API-DMAC7.html)
AU (1) AU2021310171A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179897A1 (cg-RX-API-DMAC7.html)
IL (1) IL297377A (cg-RX-API-DMAC7.html)
WO (1) WO2022012492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907353A (zh) * 2021-02-09 2022-08-16 明慧医药(杭州)有限公司 一种前药化合物及其制备方法和用途
KR20240027732A (ko) * 2021-07-20 2024-03-04 코발 바이오파마 (상하이) 컴퍼니 리미티드 외용 항염증 결합 화합물 약물 및 그 제조 방법과 응용
AU2022348759A1 (en) * 2021-09-16 2024-01-25 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof
WO2023155905A1 (zh) * 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
KR20250012423A (ko) * 2023-07-17 2025-01-24 차의과학대학교 산학협력단 금 나노입자 및 상환변환 나노입자로부터 형성된 일시적 광천공을 위한 나노복합체
WO2026002095A1 (en) * 2024-06-26 2026-01-02 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally controlled release of therapeutic agents and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1705683A (zh) * 2002-10-18 2005-12-07 菲迪尔制药公司 与透明质酸或透明质酸衍生物共价键合的紫杉烷
CN101745119A (zh) * 2010-01-25 2010-06-23 中国药科大学 羧酸类药物-多糖偶联物及其制备方法与应用
CN103751795A (zh) * 2013-05-20 2014-04-30 中国药科大学 透明质酸-抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
KR20140104637A (ko) * 2013-02-20 2014-08-29 성균관대학교산학협력단 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107096036A (zh) * 2017-04-12 2017-08-29 武汉理工大学 一种pH敏感型透明质酸‑多柔比星纳米前药的制备方法及其应用
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
WO2020122816A1 (en) * 2018-12-12 2020-06-18 Agency For Science, Technology And Research Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921347B (zh) 2004-01-07 2014-07-30 生化学工业株式会社 透明质酸衍生物及含有其的药剂
WO2006122954A2 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
IE20060565A1 (en) * 2006-07-28 2008-02-06 Eurand Pharmaceuticals Ltd Drug delivery system based on regioselectively amidated hyaluronic acid
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
US9789200B2 (en) * 2008-04-22 2017-10-17 Fidia Farmaceutici S.P.A. Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
BR112014032916A2 (pt) * 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
CN104603156B (zh) * 2012-09-05 2016-10-26 中外制药株式会社 引入有氨基酸和甾基的透明质酸衍生物
US10098962B2 (en) * 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
JOP20190245A1 (ar) * 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2021243467A1 (en) * 2020-06-05 2021-12-09 London Pharmaceuticals And Research Corporation Cannabinoid-hyaluronic acid bioconjugates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1705683A (zh) * 2002-10-18 2005-12-07 菲迪尔制药公司 与透明质酸或透明质酸衍生物共价键合的紫杉烷
CN101745119A (zh) * 2010-01-25 2010-06-23 中国药科大学 羧酸类药物-多糖偶联物及其制备方法与应用
KR20140104637A (ko) * 2013-02-20 2014-08-29 성균관대학교산학협력단 히알루론산-메토트렉세이트 접합체를 포함하는 관절염 예방 또는 치료용 약학적 조성물 및 이의 제조방법
CN103751795A (zh) * 2013-05-20 2014-04-30 中国药科大学 透明质酸-抗肿瘤药偶联物及复合纳米粒组合物的制备和应用
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
CN107096036A (zh) * 2017-04-12 2017-08-29 武汉理工大学 一种pH敏感型透明质酸‑多柔比星纳米前药的制备方法及其应用
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
WO2020122816A1 (en) * 2018-12-12 2020-06-18 Agency For Science, Technology And Research Conjugates and nanoparticles of hyaluronic acid and epigallocatechin-3-o-gallate and uses thereof

Also Published As

Publication number Publication date
CN117838875A (zh) 2024-04-09
CN115867319B (zh) 2024-01-02
CN115867319A (zh) 2023-03-28
JP2023533679A (ja) 2023-08-04
US20230256106A1 (en) 2023-08-17
CA3179897A1 (en) 2022-01-20
WO2022012492A1 (en) 2022-01-20
IL297377A (en) 2022-12-01
JP7870259B2 (ja) 2026-06-04
EP4181963A1 (en) 2023-05-24
BR112022021179A2 (pt) 2023-02-23
AU2021310171A1 (en) 2022-11-10
KR20230040957A (ko) 2023-03-23
EP4181963A4 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
CN115867319B (zh) 用于局部递送治疗剂的药物递送系统以及其用途
JP7843302B2 (ja) トリアルキン結合剤及び使用方法
US11638717B2 (en) Complex of nucleic acid medicine and multibranched lipid
AU2018246806B2 (en) Pyrrolobenzodiazepine dimer precursor and ligand-linker conjugate compound thereof
CN108699032B (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
JPWO2017057540A1 (ja) 免疫賦活活性を有する核酸誘導体
TW202144011A (zh) 治療劑及其結合物
TW202400788A (zh) 用於靶向遞送治療劑的雙環雜環及其配體
EP4615852A1 (en) Sting agonists
CN114853828B (zh) 化合物、缀合物及其用途
US20240398963A1 (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
CA3187159A1 (en) Ligand compounds, conjugates, and applications thereof
RU2847196C1 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
RU2847196C9 (ru) Система доставки лекарственных средств для локальной доставки терапевтических агентов и ее применения
HK40107352B (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
HK40107352A (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
JP2025501049A (ja) 三環式化合物、それを調製するための方法、及びその使用
HK40110475A (en) Drug delivery system for locally delivering therapeutic agents and uses thereof
RU2849554C2 (ru) Конъюгат производного ε-поли-l-лизина с лекарственным средством, промежуточные соединения и их применение
WO2026002095A1 (en) Drug delivery system for locally controlled release of therapeutic agents and uses thereof
HK40110742A (en) Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents
HK40069355B (zh) 化合物、缀合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107352

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant